The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1357
February 7, 2011
View Complete Issue         Table of Contents 2019 
Another Extended-Release Alpha2-Agonist for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Another Extended-Release Alpha2-Agonist for ADHD
February 7, 2011 (Issue: 1357)
The FDA has approved an extended-release formulation of clonidine hydrochloride (Kapvay– Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the second alpha2-adrenergic agonist approved for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Another Extended-Release Alpha2-Agonist for ADHD
Article code: 1357c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.